RA Capital Management JANX Position
Exited10-Fund ConvergenceRA Capital Management exited their position in Janux Therapeutics Inc. (JANX) in Q3 2023, after holding the stock for 3 quarters.
The position was first reported in Q1 2023 and has been tracked across 3 quarterly 13F filings.
JANX is a convergence signal: 10 specialist biotech funds hold this stock, suggesting high institutional conviction.
Short interest stands at 23.5% of float with 11.5 days to cover, indicating significant bearish positioning against the stock.
About Janux Therapeutics Inc.
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.
Full company profile →Short Interest
23.5%
11.5 days to cover
RA Capital Management JANX Position History
Frequently Asked Questions
Does RA Capital Management own JANX?
No. RA Capital Management exited their position in Janux Therapeutics Inc. (JANX) in Q3 2023. They previously held the stock for 3 quarters.
How many hedge funds own JANX?
10 specialist biotech hedge funds currently hold JANX, including OrbiMed Advisors, Cormorant Asset Management, BVF Partners and 7 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did RA Capital Management first buy JANX?
RA Capital Management's position in JANX was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is RA Capital Management's JANX position increasing or decreasing?
RA Capital Management completely exited their JANX position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
JANXCompany Page →
All fund holders, insider trades, catalysts, and cash runway
RA Capital ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →